Table 2.

Univariate analysis of factors predicting biochemical progression-free survival in high-risk localized prostate cancer patients with neoadjuvant chemohormonal therapy before radical prostatectomy (n = 21).

Factors	Univariate Hazard Ratio [95% CI] (p-Value)
Age (<65 vs. ≥65)	1.07 [0.30–3.82] (p = 0.91)
Initial PSA (≥20 vs. <20)	0.96 [0.25–3.73] (p = 0.95)
PSA density (≥ 0.4 vs. < 0.4)	0.53 [0.15–1.91] (p = 0.33)
cT (≥3 vs. <3)	0.80 [0.20–3.16] (p = 0.75)
Maximum tumor diameter before NCHT by MRI (≥20 mm vs. <20 mm)	1.41 [0.39–5.06] (p = 0.59)
Grade group (4, 5 vs. 1, 2, 3)	5.69 [0.71–45.4] (p = 0.10)
NCCN criteria (very high vs. high risk but not very high)	4.07 [1.11–14.9] (p = 0.03)
PSA after NCHT (≥1.28 vs. <1.28)	1.30 [0.37–4.62] (p = 0.69)
pT (≥3 vs. <3)	1.05 [0.22–4.98] (p = 0.95)
Extraprostatic extension (positive vs. negative)	0.53 [0.06–4.23] (p = 0.55)
Resection margin (positive vs. negative)	1.47 [0.38–5.72] (p = 0.57)
Resected lymph node number (<10 vs. ≥10)	1.68 [0.48–5.81] (p = 0.42)
Largest cross-section tumor diameter (≥20 mm vs. <20 mm)	3.77 [0.94–15.0] (p = 0.059)

Abbreviations: NCHT, neoadjuvant chemohormonal therapy; NCCN, National Comprehensive Cancer Network.